Search

Your search keyword '"Symmans, W. Fraser"' showing total 427 results
Start Over Author "Symmans, W. Fraser" Language english
427 results on '"Symmans, W. Fraser"'

1. Predictors of success in establishing orthotopic patient-derived xenograft models of triple negative breast cancer

Author

Echeverria, Gloria V., Cai, Shirong, Tu, Yizheng, Shao, Jiansu, Powell, Emily, Redwood, Abena B., Jiang, Yan, McCoy, Aaron, Rinkenbaugh, Amanda L., Lau, Rosanna, Trevarton, Alexander J., Fu, Chunxiao, Gould, Rebekah, Ravenberg, Elizabeth E., Huo, Lei, Candelaria, Rosalind, Santiago, Lumarie, Adrada, Beatriz E., Lane, Deanna L., Rauch, Gaiane M., Yang, Wei T., White, Jason B., Chang, Jeffrey T., Moulder, Stacy L., Symmans, W. Fraser, Hilsenbeck, Susan G., and Piwnica-Worms, Helen

Published
2023
Full Text
View/download PDF

3. Phase 2 study of neoadjuvant enzalutamide and paclitaxel for luminal androgen receptor-enriched TNBC: Trial results and insights into “ARness”

Author

Lim, Bora, Seth, Sahil, Yam, Clinton, Huo, Lei, Fujii, Takeo, Lee, Jangsoon, Bassett, Roland, Nasser, Sara, Ravenberg, Lisa, White, Jason, Clayborn, Alyson, Guerra, Gil, Litton, Jennifer K., Damodaran, Senthil, Layman, Rachel, Valero, Vicente, Tripathy, Debasish, Lewis, Michael, Dobrolecki, Lacey E., Lei, Jonathan, Candelaria, Rosalind, Arun, Banu, Rauch, Gaiane, Zhao, Li, Zhang, Jianhua, Ding, Qingqing, Symmans, W. Fraser, Chang, Jeffrey T., Thompson, Alastair M., Moulder, Stacy L., and Ueno, Naoto T.

Published
2024
Full Text
View/download PDF

4. A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancer

Author

Yam, Clinton, Mittendorf, Elizabeth A., Garber, Haven R., Sun, Ryan, Damodaran, Senthil, Murthy, Rashmi K., Ramirez, David, Karuturi, Meghan, Layman, Rachel M., Ibrahim, Nuhad, Rauch, Gaiane M., Adrada, Beatriz E., Candelaria, Rosalind P., White, Jason B., Ravenberg, Elizabeth, Clayborn, Alyson, Ding, Qing Qing, Symmans, W. Fraser, Prabhakaran, Sabitha, Thompson, Alastair M., Valero, Vicente, Tripathy, Debu, Huo, Lei, Moulder, Stacy L., and Litton, Jennifer K.

Published
2023
Full Text
View/download PDF

5. Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: a phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy

Author

Abuhadra, Nour, Sun, Ryan, Bassett, Jr, Roland L., Huo, Lei, Chang, Jeffrey T., Teshome, Mediget, Clayborn, Alyson R., White, Jason B., Ravenberg, Elizabeth E., Adrada, Beatriz E., Candelaria, Rosalind P., Yang, Wei, Ding, Qingqing, Symmans, W. Fraser, Arun, Banu, Damodaran, Senthil, Koenig, Kimberly B., Layman, Rachel M., Lim, Bora, Litton, Jennifer K., Thompson, Alastair, Ueno, Naoto T., Piwnica-Worms, Helen, Hortobagyi, Gabriel N., Valero, Vicente, Tripathy, Debu, Rauch, Gaiane M., Moulder, Stacy, and Yam, Clinton

Published
2023
Full Text
View/download PDF

7. Standardizing Pathologic Evaluation of Breast Carcinoma After Neoadjuvant Chemotherapy: Recommendations From the I-SPY Pathology Working Group

Author

Sahoo, Sunati, Krings, Gregor, Chen, Yunn-Yi, Carter, Jodi M., Chen, Beiyun, Guo, Hua, Hibshoosh, Hanina, Reisenbichler, Emily, Fan, Fang, Wei, Shi, Khazai, Laila, Balassanian, Ronald, Klein, Molly E., Shad, Sonal, Venters, Sara J., Borowsky, Alexander D., Symmans, W. Fraser, and Ocal, I. Tolgay

Subjects
Pathology -- Standards, Neoadjuvant therapy -- Patient outcomes, Tumor staging -- Methods -- Standards, Breast cancer -- Prognosis -- Drug therapy -- Patient outcomes, Health
Abstract

* Context.--Neoadjuvant systemic therapy refers to the use of systemic agent(s) for malignancy prior to surgical treatment and has recently emerged as an option for most breast cancer patients eligible for adjuvant systemic therapy. Consequently, treated breast carcinomas have become routine specimens in pathology practices. A standard protocol has not yet been universally adopted for the evaluation and reporting of these specimens. The American Joint Committee on Cancer staging system recognizes the challenges in staging breast carcinomas after neoadjuvant treatment and provides important data points but does not currently provide detailed guidance in estimating the residual tumor burden in the breast and lymph nodes. The Residual Cancer Burden system is the only Web-based system that quantifies treatment response as a continuous variable using residual tumor burden in the breast and the lymph nodes. Objective.--To provide clarifications and guidance for evaluation and reporting of postneoadjuvant breast specimens, discuss issues with the current staging and reporting systems, and provide specific suggestions for future modifications to the American Joint Committee on Cancer system and the Residual Cancer Burden calculator. Data Sources.--English-language literature on the subject and the data from the I-SPy 2, a multicenter, adaptive randomization phase 2 neoadjuvant platform trial for early-stage, high-risk breast cancer patients. Conclusions.--This article highlights challenges in the pathologic evaluation and reporting of treated breast carcinomas and provides recommendations and clarifications for pathologists and clinicians. It also provides specific recommendations for staging and discusses future directions. doi: 10.5858/arpa.2022-0021-EP, Neoadjuvant systemic therapy (NST) in the treatment of breast cancer involves the administration of chemotherapy (NCT) or endocrine therapy prior to definitive surgery. Initially, NCT was implemented as a standard [...]

Published
2023
Full Text
View/download PDF

8. Protein signaling and drug target activation signatures to guide therapy prioritization: Therapeutic resistance and sensitivity in the I-SPY 2 Trial

Author

Gallagher, Rosa I., Wulfkuhle, Julia, Wolf, Denise M., Brown-Swigart, Lamorna, Yau, Christina, O’Grady, Nicholas, Basu, Amrita, Lu, Ruixiao, Campbell, Michael J., Magbanua, Mark J., Coppé, Jean-Philippe, Asare, Smita M., Sit, Laura, Matthews, Jeffrey B., Perlmutter, Jane, Hylton, Nola, Liu, Minetta C., Symmans, W. Fraser, Rugo, Hope S., Isaacs, Claudine, DeMichele, Angela M., Yee, Douglas, Pohlmann, Paula R., Hirst, Gillian L., Esserman, Laura J., van ‘t Veer, Laura J., and Petricoin, Emanuel F.

Published
2023
Full Text
View/download PDF

9. Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis

Author

Garcia-Recio, Susana, Hinoue, Toshinori, Wheeler, Gregory L., Kelly, Benjamin J., Garrido-Castro, Ana C., Pascual, Tomas, De Cubas, Aguirre A., Xia, Youli, Felsheim, Brooke M., McClure, Marni B., Rajkovic, Andrei, Karaesmen, Ezgi, Smith, Markia A., Fan, Cheng, Ericsson, Paula I. Gonzalez, Sanders, Melinda E., Creighton, Chad J., Bowen, Jay, Leraas, Kristen, Burns, Robyn T., Coppens, Sara, Wheless, Amy, Rezk, Salma, Garrett, Amy L., Parker, Joel S., Foy, Kelly K., Shen, Hui, Park, Ben H., Krop, Ian, Anders, Carey, Gastier-Foster, Julie, Rimawi, Mothaffar F., Nanda, Rita, Lin, Nancy U., Isaacs, Claudine, Marcom, P. Kelly, Storniolo, Anna Maria, Couch, Fergus J., Chandran, Uma, Davis, Michael, Silverstein, Jonathan, Ropelewski, Alexander, Liu, Minetta C., Hilsenbeck, Susan G., Norton, Larry, Richardson, Andrea L., Symmans, W. Fraser, Wolff, Antonio C., Davidson, Nancy E., Carey, Lisa A., Lee, Adrian V., Balko, Justin M., Hoadley, Katherine A., Laird, Peter W., Mardis, Elaine R., King, Tari A., and Perou, Charles M.

Published
2023
Full Text
View/download PDF

11. Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy

Author

Magbanua, Mark Jesus M., Brown Swigart, Lamorna, Ahmed, Ziad, Sayaman, Rosalyn W., Renner, Derrick, Kalashnikova, Ekaterina, Hirst, Gillian L., Yau, Christina, Wolf, Denise M., Li, Wen, Delson, Amy L., Asare, Smita, Liu, Minetta C., Albain, Kathy, Chien, A. Jo, Forero-Torres, Andres, Isaacs, Claudine, Nanda, Rita, Tripathy, Debu, Rodriguez, Angel, Sethi, Himanshu, Aleshin, Alexey, Rabinowitz, Matthew, Perlmutter, Jane, Symmans, W. Fraser, Yee, Douglas, Hylton, Nola M., Esserman, Laura J., DeMichele, Angela M., Rugo, Hope S., and van ’t Veer, Laura J.

Published
2023
Full Text
View/download PDF

12. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients

Author

Adamson, Kathi, Albain, Kathy S., Asare, Adam L., Asare, Smita M., Balassanian, Ron, Beckwith, Heather, Berry, Scott M., Berry, Donald A., Boughey, Judy C., Buxton, Meredith B., Chen, Yunn-Yi, Chen, Beiyun, Chien, A. Jo, Chui, Stephen Y., Clark, Amy S., Clennell, Julia L., Datnow, Brian, DeMichele, Angela M., Duan, Xiuzhen, Edmiston, Kirsten K., Elias, Anthony D., Ellis, Erin D., Esserman, Laura L., Euhus, David M., Fadare, Oluwole, Fan, Fang, Feldman, Michael D, Forero-Torres, Andres, Haley, Barbara B., Han, Hyo S., Harada, Shuko, Haugen, Patricia, Helsten, Teresa, Hirst, Gillian L., Hylton, Nola M., Isaacs, Claudine, Kemmer, Kathleen, Khan, Qamar J., Khazai, Laila, Klein, Molly E., Krings, Gregor, Lang, Julie E., LeBeau, Lauren G., Leyland-Jones, Brian, Liu, Minetta C., Lo, Shelly, Lu, Janice, Magliocco, Anthony, Matthews, Jeffrey B., Melisko, Michelle E., Mhawech-Fauceglia, Paulette, Moulder, Stacy L., Murthy, Rashmi K., Nanda, Rita, Northfelt, Donald W., Ocal, Idris T., Olopade, Olufunmilayo, Pambuccian, Stefan, Paoloni, Melissa, Park, John W., Parker, Barbara A., Perlmutter, Jane, Peterson, Garry, Pusztai, Lajos, Rendi, Mara, Rugo, Hope S., Sahoo, Sunati, Sams, Sharon, Sanil, Ashish, Sattar, Husain, Schwab, Richard B., Singhrao, Ruby, Steeg, Katherine, Stringer-Reasor, Erica, Symmans, W. Fraser, Tawfik, Ossama, Tripathy, Debasish, Troxell, Megan L., van't Veer, Laura J., Venters, Sara J., Vinh, Tuyethoa, Viscusi, Rebecca K., Wallace, Anne M., Wei, Shi, Wilson, Amy, Yau, Christina, Yee, Douglas, Zeck, Jay C., Osdoit, Marie, van der Noordaa, Marieke, Shad, Sonal, Wei, Jane, de Croze, Diane, Hamy, Anne-Sophie, Laé, Marick, Reyal, Fabien, Sonke, Gabe S, Steenbruggen, Tessa G, van Seijen, Maartje, Wesseling, Jelle, Martín, Miguel, del Monte-Millán, Maria, López-Tarruella, Sara, Boughey, Judy C, Goetz, Matthew P, Hoskin, Tanya, Gould, Rebekah, Valero, Vicente, Edge, Stephen B, Abraham, Jean E, Bartlett, John M S, Caldas, Carlos, Dunn, Janet, Earl, Helena, Hayward, Larry, Hiller, Louise, Provenzano, Elena, Sammut, Stephen-John, Thomas, Jeremy S, Cameron, David, Graham, Ashley, Hall, Peter, Mackintosh, Lorna, Godwin, Andrew K, Schwensen, Kelsey, Sharma, Priyanka, DeMichele, Angela M, Cole, Kimberly, Kim, Mi-Ok, van 't Veer, Laura J, Esserman, Laura J, and Symmans, W Fraser

Published
2022
Full Text
View/download PDF

14. Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer

Author

Lang, Julie E., Forero-Torres, Andres, Yee, Douglas, Yau, Christina, Wolf, Denise, Park, John, Parker, Barbara A., Chien, A. Jo, Wallace, Anne M., Murthy, Rashmi, Albain, Kathy S., Ellis, Erin D., Beckwith, Heather, Haley, Barbara B., Elias, Anthony D., Boughey, Judy C., Yung, Rachel L., Isaacs, Claudine, Clark, Amy S., Han, Hyo S., Nanda, Rita, Khan, Qamar J., Edmiston, Kristen K., Stringer-Reasor, Erica, Price, Elissa, Joe, Bonnie, Liu, Minetta C., Brown-Swigart, Lamorna, Petricoin, Emanuel F., Wulfkuhle, Julia D., Buxton, Meredith, Clennell, Julia L., Sanil, Ashish, Berry, Scott, Asare, Smita M., Wilson, Amy, Hirst, Gillian L., Singhrao, Ruby, Asare, Adam L., Matthews, Jeffrey B., Melisko, Michelle, Perlmutter, Jane, Rugo, Hope S., Symmans, W. Fraser, van ‘t Veer, Laura J., Hylton, Nola M., DeMichele, Angela M., Berry, Donald A., and Esserman, Laura J.

Published
2022
Full Text
View/download PDF

15. A dedicated structured data set for reporting of invasive carcinoma of the breast in the setting of neoadjuvant therapy: recommendations from the International Collaboration on Cancer Reporting (ICCR).

Author

Bossuyt, Veerle, Provenzano, Elena, Symmans, W Fraser, Webster, Fleur, Allison, Kimberly H, Dang, Chau, Gobbi, Helenice, Kulka, Janina, Lakhani, Sunil R, Moriya, Takuya, Quinn, Cecily M, Sapino, Anna, Schnitt, Stuart, Sibbering, D Mark, Slodkowska, Elzbieta, Yang, Wentao, Tan, Puay Hoon, and Ellis, Ian

Subjects
BREAST, NEOADJUVANT chemotherapy, LOBULAR carcinoma, CARCINOMA in situ, CARCINOMA, DUCTAL carcinoma
Abstract

Aims: The International Collaboration on Cancer Reporting (ICCR), a global alliance of major (inter‐)national pathology and cancer organisations, is an initiative aimed at providing a unified international approach to reporting cancer. ICCR recently published new data sets for the reporting of invasive breast carcinoma, surgically removed lymph nodes for breast tumours and ductal carcinoma in situ, variants of lobular carcinoma in situ and low‐grade lesions. The data set in this paper addresses the neoadjuvant setting. The aim is to promote high‐quality, standardised reporting of tumour response and residual disease after neoadjuvant treatment that can be used for subsequent management decisions for each patient. Methods: The ICCR convened expert panels of breast pathologists with a representative surgeon and oncologist to critically review and discuss current evidence. Feedback from the international public consultation was critical in the development of this data set. Results: The expert panel concluded that a dedicated data set was required for reporting of breast specimens post‐neoadjuvant therapy with inclusion of data elements specific to the neoadjuvant setting as core or non‐core elements. This data set proposes a practical approach for handling and reporting breast resection specimens following neoadjuvant therapy. The comments for each data element clarify terminology, discuss available evidence and highlight areas with limited evidence that need further study. This data set overlaps with, and should be used in conjunction with, the data sets for the reporting of invasive breast carcinoma and surgically removed lymph nodes from patients with breast tumours, as appropriate. Key issues specific to the neoadjuvant setting are included in this paper. The entire data set is freely available on the ICCR website. Conclusions: High‐quality, standardised reporting of tumour response and residual disease after neoadjuvant treatment are critical for subsequent management decisions for each patient. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

17. Hormonal modulation of ESR1 mutant metastasis

Author

Gu, Guowei, Tian, Lin, Herzog, Sarah K., Rechoum, Yassine, Gelsomino, Luca, Gao, Meng, Du, Lili, Kim, Jin-Ah, Dustin, Derek, Lo, Hin Ching, Beyer, Amanda R., Edwards, David G., Gonzalez, Thomas, Tsimelzon, Anna, Huang, Helen J., Fernandez, Natalie M., Grimm, Sandra L., Hilsenbeck, Susan G., Liu, Dan, Xu, Jun, Alaniz, Alyssa, Li, Shunqiang, Mills, Gordon B., Janku, Filip, Kittler, Ralf, Zhang, Xiang H. -F., Coarfa, Cristian, Foulds, Charles E., Symmans, W. Fraser, Andò, Sebastiano, and Fuqua, Suzanne A. W.

Published
2021
Full Text
View/download PDF

19. Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness

Author

Metzger-Filho, Otto, Collier, Katharine, Asad, Sarah, Ansell, Peter J., Watson, Mark, Bae, Junu, Cherian, Mathew, O’Shaughnessy, Joyce, Untch, Michael, Rugo, Hope S., Huober, Jens B., Golshan, Mehra, Sikov, William M., von Minckwitz, Gunter, Rastogi, Priya, Li, Lang, Cheng, Lijun, Maag, David, Wolmark, Norman, Denkert, Carsten, Symmans, W. Fraser, Geyer, Jr., Charles E., Loibl, Sibylle, and Stover, Daniel G.

Published
2021
Full Text
View/download PDF

20. Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial

Author

Clark, Amy S., Yau, Christina, Wolf, Denise M., Petricoin, Emanuel F., van ‘t Veer, Laura J., Yee, Douglas, Moulder, Stacy L., Wallace, Anne M., Chien, A. Jo, Isaacs, Claudine, Boughey, Judy C., Albain, Kathy S., Kemmer, Kathleen, Haley, Barbara B., Han, Hyo S., Forero-Torres, Andres, Elias, Anthony, Lang, Julie E., Ellis, Erin D., Yung, Rachel, Tripathy, Debu, Nanda, Rita, Wulfkuhle, Julia D., Brown-Swigart, Lamorna, Gallagher, Rosa I., Helsten, Teresa, Roesch, Erin, Ewing, Cheryl A., Alvarado, Michael, Crane, Erin P., Buxton, Meredith, Clennell, Julia L., Paoloni, Melissa, Asare, Smita M., Wilson, Amy, Hirst, Gillian L., Singhrao, Ruby, Steeg, Katherine, Asare, Adam, Matthews, Jeffrey B., Berry, Scott, Sanil, Ashish, Melisko, Michelle, Perlmutter, Jane, Rugo, Hope S., Schwab, Richard B., Symmans, W. Fraser, Hylton, Nola M., Berry, Donald A., Esserman, Laura J., and DeMichele, Angela M.

Published
2021
Full Text
View/download PDF

21. Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update

Author

Allison, Kimberly H., Hammond, M. Elizabeth H., Dowsett, Mitchell, McKernin, Shannon E., Carey, Lisa A., Fitzgibbons, Patrick L., Hayes, Daniel F., Lakhani, Sunil R., Chavez-MacGregor, Mariana, Perlmutter, Jane, Perou, Charles M., Regan, Meredith M., Rimm, David L., Symmans, W. Fraser, Torlakovic, Emina E., Varella, Leticia, Viale, Giuseppe, Weisberg, Tracey F., McShane, Lisa M., and Wolff, Antonio C.

Subjects
Merck & Company Inc., Pfizer Inc., Bristol-Myers Squibb Co., AstraZeneca PLC, Ductal carcinoma in situ -- Care and treatment, Cancer prevention, Medical societies, Immunohistochemistry, Medical research, Estrogens, Progesterone, Pharmaceutical industry, Phenols (Class of compounds), Breast cancer, Carcinoma, Tumors, Sex hormones, Setting (Literature), Professional associations, Health, College of American Pathologists
Abstract

* Purpose.--To update key recommendations of the American Society of Clinical Oncology/College of American Pathologists estrogen receptor (ER) and progesterone receptor (PgR) testing in breast cancer guideline. Methods.--A multidisciplinary international Expert Panel was convened to update the clinical practice guideline recommendations informed by a systematic review of the medical literature. Recommendations.--The Expert Panel continues to recommend ER testing of invasive breast cancers by validated immunohistochemistry as the standard for predicting which patients may benefit from endocrine therapy, and no other assays are recommended for this purpose. Breast cancer samples with 1% to 100% of tumor nuclei positive should be interpreted as ER positive. However, the Expert Panel acknowledges that there are limited data on endocrine therapy benefit for cancers with 1% to 10% of cells staining ER positive. Samples with these results should be reported using a new reporting category, ER Low Positive, with a recommended comment. A sample is considered ER negative if < 1% or 0% of tumor cell nuclei are immunoreactive. Additional strategies recommended to promote optimal performance, interpretation, and reporting of cases with an initial low to no ER staining result include establishing a laboratory-specific standard operating procedure describing additional steps used by the laboratory to confirm/adjudicate results. The status of controls should be reported for cases with 0% to 10% staining. Similar principles apply to PgR testing, which is used primarily for prognostic purposes in the setting of an ER-positive cancer. Testing of ductal carcinoma in situ (DCIS) for ER is recommended to determine potential benefit of endocrine therapies to reduce risk of future breast cancer, while testing DCIS for PgR is considered optional. Additional information can be found at www.asco.org/breast-cancer-guidelines. (Arch Pathol Lab Med. 2020;144:545-563; doi: 10.5858/arpa.2019-0904-SA), INTRODUCTION First released in 2010, the American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) estrogen receptor (ER) and progesterone receptor (PgR) testing guideline is aimed at improving the [...]

Published
2020
Full Text
View/download PDF

23. Correction to: Hormonal modulation of ESR1 mutant metastasis

Author

Gu, Guowei, Tian, Lin, Herzog, Sarah K., Rechoum, Yassine, Gelsomino, Luca, Gao, Meng, Du, Lili, Kim, Jin-Ah, Dustin, Derek, Lo, Hin Ching, Beyer, Amanda R., Edwards, David G., Gonzalez, Thomas, Tsimelzon, Anna, Huang, Helen J., Fernandez, Natalie M., Grimm, Sandra L., Hilsenbeck, Susan G., Liu, Dan, Xu, Jun, Alaniz, Alyssa, Li, Shunqiang, Mills, Gordon B., Janku, Filip, Kittler, Ralf, Zhang, Xiang H. -F., Coarfa, Cristian, Foulds, Charles E., Symmans, W. Fraser, Andò, Sebastiano, and Fuqua, Suzanne A. W.

Published
2022
Full Text
View/download PDF

24. Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group

Author

Amgad, Mohamed, Stovgaard, Elisabeth Specht, Balslev, Eva, Thagaard, Jeppe, Chen, Weijie, Dudgeon, Sarah, Sharma, Ashish, Kerner, Jennifer K., Denkert, Carsten, Yuan, Yinyin, AbdulJabbar, Khalid, Wienert, Stephan, Savas, Peter, Voorwerk, Leonie, Beck, Andrew H., Madabhushi, Anant, Hartman, Johan, Sebastian, Manu M., Horlings, Hugo M., Hudeček, Jan, Ciompi, Francesco, Moore, David A., Singh, Rajendra, Roblin, Elvire, Balancin, Marcelo Luiz, Mathieu, Marie-Christine, Lennerz, Jochen K., Kirtani, Pawan, Chen, I-Chun, Braybrooke, Jeremy P., Pruneri, Giancarlo, Demaria, Sandra, Adams, Sylvia, Schnitt, Stuart J., Lakhani, Sunil R., Rojo, Federico, Comerma, Laura, Badve, Sunil S., Khojasteh, Mehrnoush, Symmans, W. Fraser, Sotiriou, Christos, Gonzalez-Ericsson, Paula, Pogue-Geile, Katherine L., Kim, Rim S., Rimm, David L., Viale, Giuseppe, Hewitt, Stephen M., Bartlett, John M. S., Penault-Llorca, Frédérique, Goel, Shom, Lien, Huang-Chun, Loibl, Sibylle, Kos, Zuzana, Loi, Sherene, Hanna, Matthew G., Michiels, Stefan, Kok, Marleen, Nielsen, Torsten O., Lazar, Alexander J., Bago-Horvath, Zsuzsanna, Kooreman, Loes F. S., van der Laak, Jeroen A. W. M., Saltz, Joel, Gallas, Brandon D., Kurkure, Uday, Barnes, Michael, Salgado, Roberto, and Cooper, Lee A. D.

Published
2020
Full Text
View/download PDF

25. Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer

Author

Kos, Zuzana, Roblin, Elvire, Kim, Rim S., Michiels, Stefan, Gallas, Brandon D., Chen, Weijie, van de Vijver, Koen K., Goel, Shom, Adams, Sylvia, Demaria, Sandra, Viale, Giuseppe, Nielsen, Torsten O., Badve, Sunil S., Symmans, W. Fraser, Sotiriou, Christos, Rimm, David L., Hewitt, Stephen, Denkert, Carsten, Loibl, Sibylle, Luen, Stephen J., Bartlett, John M. S., Savas, Peter, Pruneri, Giancarlo, Dillon, Deborah A., Cheang, Maggie Chon U., Tutt, Andrew, Hall, Jacqueline A., Kok, Marleen, Horlings, Hugo M., Madabhushi, Anant, van der Laak, Jeroen, Ciompi, Francesco, Laenkholm, Anne-Vibeke, Bellolio, Enrique, Gruosso, Tina, Fox, Stephen B., Araya, Juan Carlos, Floris, Giuseppe, Hudeček, Jan, Voorwerk, Leonie, Beck, Andrew H., Kerner, Jen, Larsimont, Denis, Declercq, Sabine, Van den Eynden, Gert, Pusztai, Lajos, Ehinger, Anna, Yang, Wentao, AbdulJabbar, Khalid, Yuan, Yinyin, Singh, Rajendra, Hiley, Crispin, Bakir, Maise al, Lazar, Alexander J., Naber, Stephen, Wienert, Stephan, Castillo, Miluska, Curigliano, Giuseppe, Dieci, Maria-Vittoria, André, Fabrice, Swanton, Charles, Reis-Filho, Jorge, Sparano, Joseph, Balslev, Eva, Chen, I-Chun, Stovgaard, Elisabeth Ida Specht, Pogue-Geile, Katherine, Blenman, Kim R. M., Penault-Llorca, Frédérique, Schnitt, Stuart, Lakhani, Sunil R., Vincent-Salomon, Anne, Rojo, Federico, Braybrooke, Jeremy P., Hanna, Matthew G., Soler-Monsó, M. Teresa, Bethmann, Daniel, Castaneda, Carlos A., Willard-Gallo, Karen, Sharma, Ashish, Lien, Huang-Chun, Fineberg, Susan, Thagaard, Jeppe, Comerma, Laura, Gonzalez-Ericsson, Paula, Brogi, Edi, Loi, Sherene, Saltz, Joel, Klaushen, Frederick, Cooper, Lee, Amgad, Mohamed, Moore, David A., and Salgado, Roberto

Published
2020
Full Text
View/download PDF

26. Pharmacologic profiling of patient-derived xenograft models of primary treatment-naïve triple-negative breast cancer

Author

Powell, Reid T., Redwood, Abena, Liu, Xuan, Guo, Lei, Cai, Shirong, Zhou, Xinhui, Tu, Yizheng, Zhang, Xiaomei, Qi, Yuan, Jiang, Yan, Echeverria, Gloria, Feng, Ningping, Ma, XiaoYan, Giuliani, Virginia, Marszalek, Joseph R., Heffernan, Timothy P., Vellano, Christopher P., White, Jason B., Stephan, Clifford, Davies, Peter J., Moulder, Stacy, Symmans, W. Fraser, Chang, Jeffrey T., and Piwnica-Worms, Helen

Published
2020
Full Text
View/download PDF

29. Author Correction: Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint

Author

Boughey, Judy C., Alvarado, Michael D., Lancaster, Rachael B., Symmans, W. Fraser, Mukhtar, Rita, Wong, Jasmine M., Ewing, Cheryl A., Potter, David A., Tuttle, Todd M., Hieken, Tina J., Carter, Jodi M., Jakub, James W., Kaplan, Henry G., Buchanan, Claire L., Jaskowiak, Nora T., Sattar, Husain A., Mueller, Jeffrey, Nanda, Rita, Isaacs, Claudine J., Pohlmann, Paula R., Lynce, Filipa, Tousimis, Eleni A., Zeck, Jay C., Lee, M. Catherine, Lang, Julie E., Mhawech-Fauceglia, Paulette, Rao, Roshni, Taback, Bret, Goodellas, Constantine, Chen, Margaret, Kalinsky, Kevin M., Hibshoosh, Hanina, Killelea, Brigid, Sanft, Tara, Hirst, Gillian L., Asare, Smita, Matthews, Jeffrey B., Perlmutter, Jane, Esserman, Laura J., and I-SPY2 Investigators

Published
2019
Full Text
View/download PDF

30. Quantifying hormone receptor status in lobular breast cancer in an institutional series: the relationship between estrogen and progesterone receptor status and outcomes.

Author

Clelland, Elle N., Rothschild, Harriet T., Patterson, Anne, Molina-Vega, Julissa, Kaur, Mandeep, Symmans, W. Fraser, Schwartz, Christopher J., Chien, A. Jo, Benz, Christopher C., and Mukhtar, Rita A.

Abstract

Purpose: Recent guidelines defined a new reporting category of ER-low-positive breast cancer based on immunohistochemistry (IHC). While low positivity of either hormone receptor is uncommon in invasive lobular carcinoma (ILC), we sought to investigate whether relatively low hormone receptor positivity was associated with tumor characteristics and patient outcomes in a single institutional cohort. Methods: We searched an institutional database for cases of stage I-III ILC with available IHC reports. Based on prior published categories in ILC, ER was classified as low, medium, or high as defined by ER staining of 10–69%, 70–89%, and ≥ 90% respectively. PR low and high tumors were defined by < 20%, or ≥ 20% staining respectively. We used chi-squared tests, t-tests, and Cox proportional hazards models to evaluate associations between ER/PR categories and tumor characteristics or disease-free survival (DFS). Results: The cohort consisted of 707 ILC cases, with 11% of cases categorized as ER low, 15.1% as medium, and 73.8% as high. The majority (67.6%) were PR high. Patients with ER low/medium expression were significantly younger, and more likely to also have PR low and/or HER2 positive tumors compared to those that were ER high. In a Cox proportional hazards model adjusting for age, stage, grade, pleomorphic histology, and treatment, ER category was not prognostic for DFS, but PR negative and PR low status each had significantly worse DFS compared to PR high status (HR 3.5, 95% CI 1.8–6.7, p < 0.001; and HR 2.0, 95% CI 1.1–3.5, p = 0.015, respectively). Conclusion: These findings highlight the relevance of quantifying ER and PR within ILC. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

31. Pre‐analytical effects on whole transcriptome and targeted RNA sequencing analysis in cytology: The effects of prolonged time in storage of effusion specimens prior to preservation.

Author

Sura, Gloria H., Tran, Kevin, Fu, Chunxiao, Du, Lili, Marczyk, Michał, Gould, Rebekah E., Chen, Eveline, Tasto, Amy M., Tinnirello, Agata A., and Symmans, W. Fraser

Subjects
RNA sequencing, EXUDATES & transudates, CYTOLOGY, TRANSCRIPTOMES
Abstract

Objectives: To investigate the pre‐analytics of the molecular testing of cytology specimens, we studied the effects of time in refrigerator storage (4°C) of malignant effusions on RNA sequencing (RNAseq) results. Methods: Ten effusion specimens were stored in a refrigerator (4°C) for different durations (day 0, 1, 4, and 7). All specimens were prepared as cytospins fixed in either Carnoy's solution or 95% ethanol (EtOH) and in an RNA preservative for a fresh frozen (FF) high‐quality reference. Whole transcriptome (wt) and targeted (t)RNAseq of two multigene expression signatures were performed. We then compared transcript expression levels (including mutant allele fraction) according to pre‐analytical variables using a concordance correlation coefficient (CCC) and a mixed effect model. Results: Sequencing results were mostly stable over increasing time in storage. Cytospins fixed in Carnoy's solution were more concordant with FF samples than cytospins fixed in 95% EtOH at all timepoints. This finding was consistent for both wtRNAseq (averages: day 0 CCC = 0.98 vs 0.91; day 7 CCC = 0.88 vs 0.78) and tRNAseq methods (averages: day 0 CCC = 0.98 vs 0.81; day 7 CCC = 0.98 vs 0.90). Cytospins fixed in Carnoy's solution did not show significant changes in expression over timepoints or between expression signatures, whereas 95% EtOH did. Conclusion: RNAseq can be accurately performed on effusion specimens after prolonged refrigerator storage. RNA extracted from scraped cytospin slides fixed in Carnoy's solution was marginally superior to 95% EtOH fixation, but either method had comparable analytic performance to high‐quality FF RNA samples. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

32. Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group

Author

Provenzano, Elena, Bossuyt, Veerle, Viale, Giuseppe, Cameron, David, Badve, Sunil, Denkert, Carsten, MacGrogan, Gaëtan, Penault-Llorca, Frédérique, Boughey, Judy, Curigliano, Giuseppe, Dixon, J Michael, Esserman, Laura, Fastner, Gerd, Kuehn, Thorsten, Peintinger, Florentia, von Minckwitz, Gunter, White, Julia, Yang, Wei, and Symmans, W Fraser

Published
2015
Full Text
View/download PDF

37. Residual Cancer Burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multi-center pooled analysis of 5161 patients

Author

C Boughey, Judy, P. Goetz, Matthew, Hoskin, Tanya, Gould, Rebekah, Valero, Vicente, B Edge, Stephen, E Abraham, Jean, Bartlett, John, Caldas, Carlos, Dunn, Janet, Earl, Helena, Hayward, Larry, Hiller, Louise, Provenzano, Elena, Sammut, Stephen-John, S Thomas, Jeremy, Cameron, David A, Graham, Ashley, Hall, Peter S, Mackintosh, Lorna, Fan, Fang, K Godwin, Andrew, Schwensen, Kelsey, Sharma, Priyanka, M DeMichele, Angela, Cole, Kimberly, Pusztai, Lajos, Kim, Mi-Ok, J Van 'T Veer, Laura, J Esserman, Laura, and Symmans, W. Fraser

Published
2021

41. PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor—positive breast cancer

Author

Loi, Sherene, Haibe-Kains, Benjamin, Majjaj, Samira, Lallemand, Francoise, Durbecq, Virginie, Larsimont, Denis, Gonzalez-Angulo, Ana M., Pusztai, Lajos, Symmans, W. Fraser, Bardelli, Alberto, Ellis, Paul, Tutt, Andrew N. J., Gillett, Cheryl E., Hennessy, Bryan T., Mills, Gordon B., Phillips, Wayne A., Piccart, Martine J., Speed, Terence P., McArthur, Grant A., Sotiriou, Christos, and Brugge, Joan S.

Published
2010

44. Association of Residual Ductal Carcinoma In Situ With Breast Cancer Recurrence in the Neoadjuvant I-SPY2 Trial.

Author

Osdoit, Marie, Yau, Christina, Symmans, W. Fraser, Boughey, Judy C., Ewing, Cheryl A., Balassanian, Ron, Chen, Yunn-Yi, Krings, Gregor, Wallace, Anne M, Zare, Somaye, Fadare, Oluwole, Lancaster, Rachael, Wei, Shi, Godellas, Constantine V., Tang, Ping, Tuttle, Todd M, Klein, Molly, Sahoo, Sunati, Hieken, Tina J., and Carter, Jodi M.

Published
2022
Full Text
View/download PDF

45. Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials

Author

Juul, Nicolai, Szallasi, Zoltan, Eklund, Aron C, Li, Qiyuan, Burrell, Rebecca A, Gerlinger, Marco, Valero, Vicente, Andreopoulou, Eleni, Esteva, Francisco J, Symmans, W Fraser, Desmedt, Christine, Haibe-Kains, Benjamin, Sotiriou, Christos, Pusztai, Lajos, and Swanton, Charles

Published
2010
Full Text
View/download PDF

48. Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers

Author

Santarpia, Libero, Qi, Yuan, Stemke-Hale, Katherine, Wang, Bailiang, Young, Elliana J., Booser, Daniel J., Holmes, Frankie A., O’Shaughnessy, Joyce, Hellerstedt, Beth, Pippen, John, Vidaurre, Tatiana, Gomez, Henry, Valero, Vicente, Hortobagyi, Gabriel N., Symmans, W. Fraser, Bottai, Giulia, Di Leo, Angelo, Gonzalez-Angulo, Ana M., and Pusztai, Lajos

Published
2012
Full Text
View/download PDF

49. Recommendations from an International Consensus Conference on the Current Status and Future of Neoadjuvant Systemic Therapy in Primary Breast Cancer

Author

Kaufmann, Manfred, von Minckwitz, Gunter, Mamounas, Elefhterios P., Cameron, David, Carey, Lisa A., Cristofanilli, Massimo, Denkert, Carsten, Eiermann, Wolfgang, Gnant, Michael, Harris, Jay R., Karn, Thomas, Liedtke, Cornelia, Mauri, Davide, Rouzier, Roman, Ruckhaeberle, Eugen, Semiglazov, Vladimir, Symmans, W. Fraser, Tutt, Andrew, and Pusztai, Lajos

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results